Transforming cancer treatment and advancing new therapies through empowered science.

Seattle Genetics is a biotechnology company focused on developing and commercializing innovative, empowered antibody-based therapies for the treatment of cancer. We are the industry leader in antibody-drug conjugates (ADCs), a technology designed to... 
Read more

NASDAQ | SGEN (Common Stock)

$66.70

0.00 (0.00%)

High$67.87
Low$66.27
Volume0
Market Cap$9,441,561,488

12/02/16  4:00 p.m. ET

Minimum 20 minute delay

Latest Investor Information

Press Releases

Takeda and Seattle Genetics Report Positive Phase 3 ALCANZA Clinical Trial Data of ADCETRIS® (Brentuximab Vedotin) for CD30-Expressing Cutaneous T-Cell Lymphoma 12/03/16

Read more

Seattle Genetics Presents Phase 1b Data from Vadastuximab Talirine (SGN-CD33A; 33A) in Combination with Standard of Care in Frontline Acute Myeloid Leukemia at ASH Annual Meeting 12/03/16

Read more

Events

58th American Society of Hematology (ASH) Annual Meeting12/05/16 8:15 p.m. PTView eventCredit Suisse 25th Annual Healthcare Conference11/08/16 12:00 p.m. ETView event
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources